14
Nov
2018

From Nova Scotia to the Forefront of Bio & Tech Investing: Julie Sunderland of Biomatics on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

From Computational Discovery to a New Psoriasis Drug: Jeb Keiper on The Long Run
From Musician to Tech to Biotech Investor: D.A. Wallach on The Long Run
A New Way to Treat Depression: Barry Greene on The Long Run
Delivery of Genetic Medicines: Shehnaaz Suliman on The Long Run